He walked away from Prolanta like he did Somavert. With Somavert, Pfizer stepped in and purchased the rights to develop and test the drug in clinical trials. Wen Chen and Ohio State get paid millions per year in royalties from their licensing agreement with Pfizer. Chen basically invents a drug, finds a pharmaceutical company willing to pay a sum up front to develop it, and he moves on to research something new. If one of his inventions hits the market, he cashes in big time like he has with Somavert.
He's so well off right now that whatever happens with Prolanta's success is of little concern to him.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.